» Articles » PMID: 7815321

Bidirectional Effects of Endogenous Opioid Peptides on Endothelin Release Rates in Porcine Aortic Endothelial Cell Culture: Mediation by Delta Opioid Receptor and Opioid Receptor Antagonist-insensitive Mechanisms

Overview
Specialty Pharmacology
Date 1995 Jan 1
PMID 7815321
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The effects of opioid peptides on immunoreactive endothelin (ir ET) release from cultured porcine aortic endothelial cells over a 1-hr period (4-5 or 23-24 hr) were determined by radioimmunoassay and high-performance liquid chromatography after treatment for either 4 or 23 hr. Endogenous opioids, the synthetic delta opioid [D-Pen2,5]enkephalin and, for comparison, atrial and brain natriuretic peptides were added to the culture medium in concentrations ranging from 10(-12) to 10(-7) M. Thrombin (0.1-10 U/ml) served as a stimulatory reference. 1) Brain natriuretic peptide displayed only insignificant effects on ir ET release at 5 hr, but strongly inhibited ir ET release at 24 hr. 2) Opioids modulated release rates at 5 hr but did not display significant effects at 24 hr: metorphamide with predominant mu/kappa and weak delta opioid receptor activity stimulated release in a dose-dependent manner, whereas [Met5]enkephalin-Arg6-Phe7 with mu/delta activity and the delta agonists [Leu5]enkephalin, sulfated [Leu5]enkephalin and [D-Pen2,5]enkephalin decreased release rates; [Leu5]enkephalin was the most potent of the latter drugs. 3) Coincubation with either the nonselective opioid receptor antagonist naloxone (10(-5) M) or the delta receptor-selective antagonist ICI-174,864 (N,N-bisallyl-Tyr-D-Ala-Aib-Aib-Phe-Leu-OH) (10(-5) M) abolished all opioid-induced inhibitory effects, but rather potentiated or unmasked stimulatory effects of opioid peptides on ir ET release rates at 5 hr and also at 24 hr in the case of the delta agonists.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Delta Opioid Peptide Targets Brain Microvascular Endothelial Cells Reducing Apoptosis to Relieve Hypoxia-Ischemic/Reperfusion Injury.

Zhang R, Chen M, Deng Z, Kong L, Shen B, Zhang L Pharmaceutics. 2023; 15(1).

PMID: 36678674 PMC: 9861451. DOI: 10.3390/pharmaceutics15010046.


Plasma Pro-Enkephalin A and Ischemic Stroke Risk: The Reasons for Geographic and Racial Differences in Stroke Cohort.

Short S, Wilkinson K, Long D, Judd S, Schulte J, Kissela B J Stroke Cerebrovasc Dis. 2021; 31(2):106237.

PMID: 34896817 PMC: 8792292. DOI: 10.1016/j.jstrokecerebrovasdis.2021.106237.


Dynorphins in Development and Disease: Implications for Cardiovascular Disease.

Cissom C, Paris J, Shariat-Madar Z Curr Mol Med. 2019; 20(4):259-274.

PMID: 31746302 PMC: 7457512. DOI: 10.2174/1566524019666191028122559.


Effects of Low-dose Morphine on Nitric Oxide Concentration and Angiogenesis in Two-kidney One Clip Hypertensive Rats.

Pourshanazari A, Allahtavakoli M, Hassanshahi G Iran J Basic Med Sci. 2013; 14(6):560-7.

PMID: 23493527 PMC: 3586858.


Perivascular expression and potent vasoconstrictor effect of dynorphin A in cerebral arteries.

Ruisanchez E, Cselenyak A, Papp R, Nemeth T, Kaldi K, Sandor P PLoS One. 2012; 7(5):e37798.

PMID: 22662226 PMC: 3360594. DOI: 10.1371/journal.pone.0037798.